CURE Pharmaceutical is a fully integrated life science company committed to improving drug efficacy, safety and the patient experience through its proprietary drug dosage forms and delivery systems. CURE has an industry leading full service cGMP manufacturing facility and is a preeminent developer and manufacturer of a patented and proprietary delivery system (CureFilm™), the most advanced oral thin film on the market today. CURE has developed an array of products in cutting-edge delivery platforms and partners with leading pharmaceutical companies. CURE has positioned itself to advance numerous therapeutic categories, including the pharmaceutical cannabis sector with partnerships in the U.S., Canada, Israel and Germany, among other markets. The Company’s mission is to improve people’s lives by redefining how medicines are delivered and experienced.
This press release contains forward-looking statements that involve risks and uncertainties. There are important factors that could cause actual results to differ materially from those in the forward-looking statements. These factors include, without limitation, the ability to successfully market our products, the difficulty in predicting the timing or outcome of other product research and development efforts, potential product characteristics and indications, marketing approvals and launches of other products, the impact of pharmaceutical industry regulation, the impact of competitive products and pricing, the acceptance and demand of new pharmaceutical products, the impact of patents and other proprietary rights held by competitors and other third parties and the ability to obtain financing on favorable terms. The forward-looking statements in this press release reflect the Company’s judgment as of the date of this press release. The Company disclaims any intent or obligation to update these forward-looking statements. This press release shall not constitute an offer to sell or the solicitation of an offer to buy nor shall there be any sale of our securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction. On February 28, 2017, and ending on August 28, 2020, Liviakis Financial Communications, Inc. (LFC) was retained by CURE Pharmaceutical Holding Corp. (CURR) in various consulting capacities including strategic management planning, investor relations and other business development responsibilities. LFC was compensated 1,000,000 restricted common stock under rule 144. Officers and employees of LFC will buy or sell shares in CURE Pharmaceutical Holding Corp. prior, during or after this release. LFC advises CURE Pharmaceutical Holding Corp. but does not provide investment advice. LFC is not a registered investment advisor or broker-dealer. All material provided regarding CURE Pharmaceuticals Holding Corp. including, but not limited to its history, corporate status, and other developments was prepared using information approved and signed off by CURE Pharmaceutical Holding Corp. management as approved for public dissemination. Although the information contained herein is believed to be reliable, LFC makes no warranties as to the accuracy of the description of any of the content herein and accepts no liability for how readers may choose to utilize it.
Innovations in Medicine
Featuring Rob Davidson. The Cure Pharmaceutical interest is featured at the 10 minute mark.